Mirum Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Mirum Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 26.1 times by its yearly operating cash. Higher than 91% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 63% of Healthcare companies in United States.
Cash Locked Ratio
$23For every $100 of sales, $23 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $24 tied up three years earlier.
Less money tied up than 51% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$25Sales grew 576% in 3 years; of every extra $100 of sales, $25 became extra profit.
Higher than 55% of Healthcare companies in United States.
Asset Productivity Ratio
+576% / +139%In 3 years sales changed by +576% while total assets changed by +139%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
26.1×Debt due within a year is covered 26.1 times by its yearly operating cash.
Higher than 91% of Healthcare companies in United States.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Lower than 66% of Healthcare companies in United States.
Tangible Assets Ratio
69%Of every $100 the company owns, $69 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 63% of Healthcare companies in United States.
Tangible Net Worth Ratio
17%Of every $100 of net worth, $17 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 66% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Mirum Pharmaceuticals, Inc. made a loss over the last year. Mirum Pharmaceuticals, Inc. owes $1.01 for every $1 it owns. Mirum Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMirum Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-500.85Mirum Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$5.2 BThe total market value of all of Mirum Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 85% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeMirum Pharmaceuticals, Inc.'s net worth is negative ($10 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-703.0%Mirum Pharmaceuticals, Inc. lost 703.0% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
Owes vs Owns
1.01×Mirum Pharmaceuticals, Inc. owes $1.01 for every $1 it owns, so it owes more than it owns, higher than 87% of Healthcare companies in United States.
Dividend yield
NoneMirum Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+55%Revenue rose 55% in the year to Dec 2025, and grew 89% a year on average over 3 years.
Profit growth
LossMirum Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-4.5%Mirum Pharmaceuticals, Inc. lost $4 for every $100 of revenue.
Interest cover
Not coveredMirum Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashMirum Pharmaceuticals, Inc. held $64 M more cash than debt (net cash) at Dec 2025.
Questions
What is Mirum Pharmaceuticals, Inc.'s return on equity?
Mirum Pharmaceuticals, Inc. lost 703.0% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
How much does Mirum Pharmaceuticals, Inc. owe compared with what it owns?
Mirum Pharmaceuticals, Inc. owes $1.01 for every $1 it owns, so it owes more than it owns, higher than 87% of Healthcare companies in United States.
Does Mirum Pharmaceuticals, Inc. pay a dividend?
No. Mirum Pharmaceuticals, Inc. does not currently pay a dividend.
Is Mirum Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 55% in the year to Dec 2025, and grew 89% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.